Wu, C.-P.; Li, Y.-C.; Murakami, M.; Hsiao, S.-H.; Lee, Y.-C.; Huang, Y.-H.; Chang, Y.-T.; Hung, T.-H.; Wu, Y.-S.; Ambudkar, S.V.
Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells. Int. J. Mol. Sci. 2023, 24, 13972.
https://doi.org/10.3390/ijms241813972
AMA Style
Wu C-P, Li Y-C, Murakami M, Hsiao S-H, Lee Y-C, Huang Y-H, Chang Y-T, Hung T-H, Wu Y-S, Ambudkar SV.
Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells. International Journal of Molecular Sciences. 2023; 24(18):13972.
https://doi.org/10.3390/ijms241813972
Chicago/Turabian Style
Wu, Chung-Pu, Yen-Ching Li, Megumi Murakami, Sung-Han Hsiao, Yun-Chieh Lee, Yang-Hui Huang, Yu-Tzu Chang, Tai-Ho Hung, Yu-Shan Wu, and Suresh V. Ambudkar.
2023. "Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells" International Journal of Molecular Sciences 24, no. 18: 13972.
https://doi.org/10.3390/ijms241813972
APA Style
Wu, C.-P., Li, Y.-C., Murakami, M., Hsiao, S.-H., Lee, Y.-C., Huang, Y.-H., Chang, Y.-T., Hung, T.-H., Wu, Y.-S., & Ambudkar, S. V.
(2023). Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells. International Journal of Molecular Sciences, 24(18), 13972.
https://doi.org/10.3390/ijms241813972
